Trials / Unknown
UnknownNCT03818282
Efficacy and Safety of Paclitaxel for Injection (Albumin-bound) for First-line Chemotherapy of Ovarian Cancer
Efficacy and Safety of Paclitaxel for Injection (Albumin-bound) in Combination With Carboplatin for First-line Chemotherapy of Ovarian Cancer: A Multicenter, Open-label, Single-arm Phase 2 Clinical Study
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 77 (estimated)
- Sponsor
- Huazhong University of Science and Technology · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Preliminary evaluation of the efficacy and safety of paclitaxel for injection (albumin-bound) in combination with carboplatin for first-line chemotherapy of ovarian cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Paclitaxel for injection (albumin-bound) | Paclitaxel for injection (albumin-bound) 260 mg/m2, i.v., d1; AUC = 5 for carboplatin injection, i.v., infusion completed on day 1-3; Repeated every 3-4 weeks for 6-8 cycles. |
Timeline
- Start date
- 2019-03-01
- Primary completion
- 2023-06-30
- Completion
- 2024-12-31
- First posted
- 2019-01-28
- Last updated
- 2019-02-26
Source: ClinicalTrials.gov record NCT03818282. Inclusion in this directory is not an endorsement.